Medicine@Yale

The center will have an ambitious goal: to produce better diagnoses, treatments, and ultimately cures for these diseases. It will also work toward vaccine development.

Seventeen years after it began, in 2005, publication of Medicine@Yale is coming to an end with this issue.

In his new role, Winer is working to promote paradigm-changing dis- covery and to build an unparalleled clinical program that offers seamless, multidisciplinary care and clinical trials to all patients, eliminating dis- parities in access, care, and outcomes.

Isaac Y. Kim, MD, PhD, MBA, was appointed chair of the Department of Urology at Yale School of Medicine (YSM) and chief of Urology at Yale New Haven Hospital.

McGovern will participate actively in the senior leadership group of the medical school’s academic health system and play a key role in setting and realizing strategic goals. As deputy dean for clinical affairs, she will serve as the physician leader who represents the clinical mission of the School of Medicine in all venues.

Damage to nerves of the brain and spinal cord is particularly devastating because these nerves do not grow back on their own. Perhaps, suggests a Yale-led study, they could regrow with a little help from science.

This result highlights the importance of studying ASD in females rather than assuming that what is true for mostly male study populations also applies to females.

Inductees are singled out for their clinical accomplishments and their research

This is the third CTSA renewal for Yale, which was the only site in New England to receive funding when the program began in 2006.

Before COVID-19, some Yale researchers had worked for years in other vaccine development efforts focused on conquering some the world’s most malicious and deadly diseases. Those efforts continue on trajectories that may be reshaped by knowledge gained from the COVID-19 experience.